MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL)

Historical Holders from Q2 2016 to Q4 2025

Symbol
MDGL on Nasdaq
Type / Class
Equity / Common Stock, Par Value $0.0001 Per Share
Shares outstanding
23,267,064
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
23,387,152
Holdings value
$10,722,579,324
% of all portfolios
0.02%
Number of holders
347
Number of buys
187
Number of sells
145
Average buys %
+0%
Average sells %
-0.01%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 8.3% -16% $845,168,195 -$160,101,236 1,842,690 -16% JANUS HENDERSON GROUP PLC 30 Sep 2025
FRIEDMAN PAUL A 7.8% $982,730,986 1,814,831 Paul A Friedman, M.D. 10 Dec 2025
Taub Rebecca 7.8% $982,730,986 1,814,831 Rebecca Taub, M.D. 10 Dec 2025
As of 30 Sep 2025 MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL) has 347 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 23,387,152 shares of the company stock as of 30 Sep 2025.

Institutional Holders of MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 996 $579,363 +$69,826 $581.96 2
2025 Q3 23,387,152 $10,722,579,324 -$21,990,251 $458.66 347
2025 Q2 23,552,943 $7,127,866,991 -$58,976,553 $302.64 303
2025 Q1 23,618,790 $7,815,274,189 +$242,480,129 $331.23 317
2024 Q4 22,954,039 $7,083,805,672 +$127,209,746 $308.57 282
2024 Q3 22,638,348 $4,763,047,302 -$106,585,037 $212.22 252
2024 Q2 22,870,011 $6,408,116,328 +$504,945,812 $280.16 255
2024 Q1 21,107,869 $5,634,735,243 +$377,318,349 $267.04 263
2023 Q4 19,769,303 $4,574,587,850 +$602,581,939 $231.38 225
2023 Q3 17,386,191 $2,539,343,386 +$349,378,221 $146.04 206
2023 Q2 14,848,153 $3,429,412,203 +$220,213,706 $231.00 208
2023 Q1 13,867,567 $3,359,361,973 +$106,522,160 $242.26 221
2022 Q4 13,305,897 $3,862,135,682 +$567,009,121 $290.25 186
2022 Q3 11,751,595 $763,791,382 -$25,263,206 $64.99 133
2022 Q2 12,001,137 $857,568,681 -$17,315,431 $71.58 130
2022 Q1 12,025,725 $1,179,864,073 +$26,264,521 $98.12 132
2021 Q4 11,953,948 $1,012,214,597 +$40,893,478 $84.74 139
2021 Q3 10,962,747 $874,847,601 -$34,316,604 $79.79 126
2021 Q2 11,229,236 $1,093,866,439 -$99,083,348 $97.41 147
2021 Q1 12,210,439 $1,427,893,568 -$10,189,929 $116.97 135
2020 Q4 12,273,522 $1,364,432,852 +$68,881,092 $111.17 132
2020 Q3 11,637,870 $1,381,764,563 +$46,463,709 $118.73 125
2020 Q2 11,257,505 $1,274,820,026 +$4,793,161 $113.25 124
2020 Q1 11,048,035 $737,557,931 +$26,608,051 $66.76 106
2019 Q4 10,473,886 $954,273,764 +$65,909,446 $91.11 119
2019 Q3 9,642,874 $831,383,218 -$23,303 $86.22 108
2019 Q2 9,609,887 $1,007,125,218 +$10,337,419 $104.81 115
2019 Q1 9,458,074 $1,184,436,498 +$61,292,852 $125.26 133
2018 Q4 8,980,955 $1,012,211,915 -$4,919,869 $112.72 130
2018 Q3 8,620,856 $1,846,093,673 +$62,737,488 $214.13 153
2018 Q2 8,122,360 $2,271,715,929 +$574,219,732 $279.69 148
2018 Q1 6,326,097 $738,823,289 +$151,724,184 $116.79 98
2017 Q4 5,126,558 $470,559,417 +$234,134,618 $91.79 88
2017 Q3 2,673,071 $120,236,161 +$28,988,629 $44.98 50
2017 Q2 2,046,899 $33,282,527 +$8,857,871 $16.26 39
2017 Q1 1,529,190 $23,547,216 +$3,024,176 $15.40 25
2016 Q4 1,345,552 $20,048,209 +$6,295,667 $14.90 24
2016 Q3 1,006,962 $12,766,000 +$12,739,000 $12.67 24
2016 Q2 79,573 $21,000 +$21,000 $0.2639 1